All In Biotech

Drug Trial Radar · NCT02768298

Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

A Randomized, Double-blind, Active-controlled Study to Assess the Effect of LCZ696 Compared With Enalapril to Improve Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF).

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 201 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

201

Actual

Start

Jul 12, 2016

Primary completion

Nov 25, 2019

Study completion Nov 25, 2019

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 11, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study was to determine the effect of LCZ696 vs. enalapril on improvement of exercise capacity in patients with chronic heart failure with reduced ejection fraction.

Conditions

  • Chronic Heart Failure With Reduced Ejection Fraction

Interventions

  • LCZ696Drug

    LCZ696 100 mg bid for 2 weeks followed by LCZ696 200 mg bid for 10 weeks. Treatment was administered as oral tablets.

  • EnalaprilDrug

    Enalapril 5 mg bid for 2 weeks followed by enalapril 10 mg bid for 10 weeks. Treatment was administered as oral tablets. Patients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid.

  • Placebo matching enalaprilDrug

    Patients randomized to LCZ696 arm also received placebo matching enalapril (enalapril 0 mg tablets) to ensure the blinding during the entire course of the study.

  • Placebo matching LCZ696Drug

    Patients randomized to enalapril arm also received placebo matching LCZ696 (LCZ696 0 mg tablets) to ensure the blinding during the entire course of the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Peak Respiratory Oxygen Uptake (VO2peak) Adjusted to Body Weight) After 3 Months of TreatmentTime frame: Baseline, 3 months

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Bonn, Germany

  • Novartis Investigative Site

    Cologne, Germany

  • Novartis Investigative Site

    Cologne, Germany

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Erfurt, Germany

  • Novartis Investigative Site

    Frankfurt, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, Germany

  • Novartis Investigative Site

    Göttingen, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Heidelberg, Germany

  • Novartis Investigative Site

    Kiel, Germany

  • Novartis Investigative Site

    Koblenz, Germany

  • Novartis Investigative Site

    Koeln-Nippes, Germany

  • Novartis Investigative Site

    Leverkusen, Germany

  • Novartis Investigative Site

    Ludwigsburg, Germany

  • Novartis Investigative Site

    Ludwigshafen, Germany

  • Novartis Investigative Site

    München, Germany

  • Novartis Investigative Site

    Neuwied, Germany

  • Novartis Investigative Site

    Nienburg, Germany

  • Novartis Investigative Site

    Rotenburg an der Fulda, Germany

  • Novartis Investigative Site

    Rüdersdorf, Germany

  • Novartis Investigative Site

    Siegen, Germany

  • Novartis Investigative Site

    Ulm, Germany

  • Novartis Investigative Site

    Villingen-Schwenningen, Germany

  • Novartis Investigative Site

    Worms, Germany

  • Novartis Investigative Site

    Wuppertal, Germany

  • Novartis Investigative Site

    Würzburg, Germany

  • Novartis Investigative Site

    Regensburg, Bavaria, Germany

  • Novartis Investigative Site

    Dresden, Saxony, Germany

  • Novartis Investigative Site

    Berlin, State of Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.